Healthcare >> Analyst Interviews >> November 15, 2010
Robyn Karnauskas returned to Deutsche Bank as Director in April 2010. She provides lead equity research coverage of the biotechnology sector in North America. Ms. Karnauskas' return further demonstrates Deutsche Bank's commitment to maintaining the firm's solid track record in providing fundamental and thoughtful research in the biotech sector and throughout its broad health care platform. Ms. Karnauskas rejoins Deutsche Bank after a brief time at Morgan Stanley. Prior to that, she was Vice President and lead coverage Analyst on small and mid-cap biotech stocks at Deutsche Bank. She played an integral part in Deutsche Bank's number one Institutional Investor-ranked biotech franchise and was named Institutional Investor's "Up and Comer" Biotech Analyst in 2009. Ms. Karnauskas originally joined Deutsche Bank from Bear Stearns in 2008. She holds a Ph.D. in cancer biology from the University of Chicago and a B.S. in biology from the Massachusetts Institute of Technology. Profile
TWST: What major trends are you watching in the biotech space?
Ms. Karnauskas: In biotech we are seeing several trends, one of which is that several of the large-cap biotech companies have declining
